Is Twist Bioscience Corp well-positioned for December economic uncertainties?

As many millenniums are trying to avoid healthcare space, it makes sense to review Twist Bioscience Corp a little further and try to understand its current market patterns. We will evaluate why recent Twist Bioscience price moves suggest a bounce in December. Is Twist Bioscience Corp valuation justified? Here I will cover 2022 perspective on the current valuation of the entity to give you a better outlook on taking a possible position in this stock.
Published over two months ago
View all stories for Twist Bioscience | View All Stories
This firm currently holds 78.6 M in liabilities with Debt to Equity (D/E) ratio of 0.1, which may suggest the firm is not taking enough advantage from borrowing. Twist Bioscience is UNDERVALUED at 52.96 per share with modest projections ahead.

Twist Bioscience Corp Investment Alerts

Twist investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Twist Bioscience Corp performance across your portfolios.Please check all investment alerts for Twist

Twist Bioscience Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Twist value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Twist Bioscience competition to find correlations between indicators driving the intrinsic value of Twist.

How does Twist utilize its cash?

To perform a cash flow analysis of Twist Bioscience, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Twist Bioscience is receiving and how much cash it distributes out in a given period. The Twist Bioscience cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Twist Bioscience Net Cash Flow from Operations is comparatively stable at the moment as compared to the past year. Twist Bioscience reported Net Cash Flow from Operations of (129.08 Million) in 2022

Another Deeper Perspective

The big decline in price over the last few months for Twist Bioscience created some momentum for private investors as it was traded today as low as 25.62 and as high as 29.5 per share. The company executives failed to add value to investors and position the company supply of money to exploit market volatility in October. However, diversifying your holdings with Twist Bioscience Corp or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.54. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Twist Bioscience Corp partners.


Twist Bioscience Net Income Per Employee is increasing over the last 7 years. Moreover, Twist Bioscience Revenue Per Employee is increasing over the last 7 years.

Will Twist pull back in December 2022?

The value at risk is down to -10.22 as of today.
As of the 18th of November 2022, Twist Bioscience has the coefficient of variation of (864.13), and Risk Adjusted Performance of (0.16). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Twist Bioscience Corp, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We are able to interpolate and collect nineteen technical drivers for Twist Bioscience Corp, which can be compared to its competition. Please validate Twist Bioscience Corp coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Twist Bioscience is priced more or less accurately, providing market reflects its prevalent price of 25.76 per share. Given that Twist Bioscience Corp has jensen alpha of (0.72), we advise you to double-check Twist Bioscience Corp's current market performance to make sure the company can sustain itself at a future point.

Our Final Take On Twist Bioscience

Whereas some firms within the diagnostics & research industry are still a little expensive, even after the recent corrections, Twist Bioscience may offer a potential longer-term growth to private investors. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither buy nor trade any shares of Twist Bioscience at this time. The Twist Bioscience Corp risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Twist Bioscience.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Aina Ster do not own shares of Twist Bioscience Corp. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com